0.3998USD-69.25%Mkt Cap: —P/E: —1d ago
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also …
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)1.80M $
Gross Profit566.31K $
Net Income (TTM)-8.23M $
Revenue/Share0.1510 USD
Last Price0.3998 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.81
EPS (TTM)-0.51
EPS (Forward)—
52W Range
0.39980% of range4.500
52W High4.500 USD
52W Low0.3998 USD
Profitability
Gross Margin27.81%
Oper. Margin-289.42%
EBITDA Margin0.00%
Profit Margin-404.08%
ROE-123.21%
ROA-109.03%
Growth
Revenue Growth-35.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.13M $
CapEx (TTM)5.32K $
FCF Margin-95.65%
FCF Yield—
Net Debt-3.77M $
Net Debt/EBITDA0.47
Balance Sheet
Debt/Equity0.04
Current Ratio5.26
Quick Ratio4.82
Book Value/Sh0.4930 USD
Cash/Share0.3300 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float5.28M
Insiders—
Institutions—
Technical
SMA 500.6576 (-39.2%)
SMA 2001.204 (-66.8%)
Beta1.97
S&P 52W Chg18.16%
Avg Vol (30d)513
Avg Vol (10d)50
Technical Indicators
RSI (14)20.1
MACD-0.0754
MACD Signal-0.0118
MACD Hist.-0.0635
BB Upper1.796 USD
BB Middle1.259 USD
BB Lower0.7222 USD
BB Width85.29%
ATR (14)0.1396 USD
Vol Ratio (20d)0.16x